Polyrizon Ltd. Retains Nasdaq Listing After Addressing Compliance Concerns, Aims to Regain Minimum Bid Price by October 2025

Reuters
07-15
<a href="https://laohu8.com/S/PLRZ">Polyrizon Ltd.</a> Retains Nasdaq Listing After Addressing Compliance Concerns, Aims to Regain Minimum Bid Price by October 2025

Raanana, Israel, July 15, 2025 - Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in intranasal hydrogels, has successfully retained its listing on the Nasdaq Capital Market. Following a hearing on June 26, 2025, the Nasdaq Hearings Panel granted Polyrizon's request to continue its listing, provided the company complies with the Minimum Bid Price Rule by October 17, 2025. The company has committed to avoiding complex or dilutive financing instruments in future capital-raising activities and is implementing an internal control framework to ensure compliance with Nasdaq standards. CEO Tomer Izraeli expressed optimism about enhancing shareholder value and strengthening the company's business position.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9494649-en) on July 15, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10